Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Study on the Efficacy and Safety of hemay005 Tablets in the Treatment of Active Ankylosing Spondylitis

NCT05407246 is registered in ClinicalTrials.gov with Tianjin Hemay Pharmaceutical Co., Ltd as lead sponsor.

NCT NCT05407246
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05407246 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Study on the Efficacy and Safety of hemay005 Tablets in the Treatment of Active Ankylosing Spondylitis
Lead sponsor
Tianjin Hemay Pharmaceutical Co., Ltd
Phase
Phase 2
Overall status
Completed
Start date
August 5, 2022
Completion date
August 18, 2023
Enrollment
90 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

active ankylosing spondylitis